{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:34:12Z","timestamp":1794555252131,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neuroblastomas harbor\n                    <jats:italic>ALK<\/jats:italic>\n                    aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children and adults with relapsed or refractory ALK-driven neuroblastoma. The trial is ongoing, and we report here on three cohorts that have met pre-specified primary endpoints: lorlatinib as a single agent in children (12\u2009months to &lt;18\u2009years); lorlatinib as a single agent in adults (\u226518\u2009years); and lorlatinib in combination with topotecan\/cyclophosphamide in children (&lt;18\u2009years). Primary endpoints were safety, pharmacokinetics and recommended phase 2 dose (RP2D). Secondary endpoints were response rate and\n                    <jats:sup>123<\/jats:sup>\n                    I-metaiodobenzylguanidine (MIBG) response. Lorlatinib was evaluated at 45\u2013115\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/dose in children and 100\u2013150\u2009mg in adults. Common adverse events (AEs) were hypertriglyceridemia (90%), hypercholesterolemia (79%) and weight gain (87%). Neurobehavioral AEs occurred mainly in adults and resolved with dose hold\/reduction. The RP2D of lorlatinib with and without chemotherapy in children was 115\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . The single-agent adult RP2D was 150\u2009mg. The single-agent response rate (complete\/partial\/minor) for &lt;18\u2009years was 30%; for \u226518\u2009years, 67%; and for chemotherapy combination in &lt;18\u2009years, 63%; and 13 of 27 (48%) responders achieved MIBG complete responses, supporting lorlatinib\u2019s rapid translation into active phase 3 trials for patients with newly diagnosed high-risk, ALK-driven neuroblastoma. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03107988\">NCT03107988<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02297-5","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T12:04:55Z","timestamp":1680523495000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results"],"prefix":"10.1038","volume":"29","author":[{"given":"Kelly C.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemily","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Yun","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Groshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith G.","family":"Villablanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Krytska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian M.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Goodarzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Pawel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ghazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"States","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7842-2068","authenticated-orcid":false,"given":"Louis","family":"Chesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghan","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami V.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajen","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-1108","authenticated-orcid":false,"given":"Daniel A.","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Shusterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-9180","authenticated-orcid":false,"given":"Margaret E.","family":"Macy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-6710","authenticated-orcid":false,"given":"Navin","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-5879","authenticated-orcid":false,"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieuhoa","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger C.","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-7765","authenticated-orcid":false,"given":"Joseph","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Liyanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson","family":"Peltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther R.","family":"Berko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-7929","authenticated-orcid":false,"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araz","family":"Marachelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-0399","authenticated-orcid":false,"given":"Yael P.","family":"Moss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"2297_CR1","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","volume":"2","author":"KK Matthay","year":"2016","unstructured":"Matthay, K. K. et al. Neuroblastoma. Nat. Rev. Dis. Prim. 2, 16078 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2297_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","volume":"455","author":"Y Chen","year":"2008","unstructured":"Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971\u2013974 (2008).","journal-title":"Nature"},{"key":"2297_CR3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","volume":"455","author":"RE George","year":"2008","unstructured":"George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975\u2013978 (2008).","journal-title":"Nature"},{"key":"2297_CR4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","volume":"455","author":"I Janoueix-Lerosey","year":"2008","unstructured":"Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967\u2013970 (2008).","journal-title":"Nature"},{"key":"2297_CR5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","volume":"455","author":"YP Moss\u00e9","year":"2008","unstructured":"Moss\u00e9, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930\u2013935 (2008).","journal-title":"Nature"},{"key":"2297_CR6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","volume":"47","author":"TF Eleveld","year":"2015","unstructured":"Eleveld, T. F. et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet. 47, 864\u2013871 (2015).","journal-title":"Nat. Genet."},{"key":"2297_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3349","volume":"47","author":"A Schramm","year":"2015","unstructured":"Schramm, A. et al. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872\u2013877 (2015).","journal-title":"Nat. Genet."},{"key":"2297_CR8","doi-asserted-by":"crossref","first-page":"e1006501","DOI":"10.1371\/journal.pgen.1006501","volume":"12","author":"OM Padovan-Merhar","year":"2016","unstructured":"Padovan-Merhar, O. M. et al. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet. 12, e1006501 (2016).","journal-title":"PLoS Genet."},{"key":"2297_CR9","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2013.54.0674","volume":"32","author":"G Schleiermacher","year":"2014","unstructured":"Schleiermacher, G. et al. Emergence of new ALK mutations at relapse of neuroblastoma. J. Clin. Oncol. 32, 2727\u20132734 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2297_CR10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","volume":"30","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30, 1121\u20131126 (2019).","journal-title":"Ann. Oncol."},{"key":"2297_CR11","doi-asserted-by":"crossref","first-page":"108ra114","DOI":"10.1126\/scitranslmed.3002950","volume":"3","author":"SC Bresler","year":"2011","unstructured":"Bresler, S. C. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci. Transl. Med. 3, 108ra114 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2297_CR12","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","volume":"22","author":"M Fischer","year":"2021","unstructured":"Fischer, M. et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 22, 1764\u20131776 (2021).","journal-title":"Lancet Oncol."},{"key":"2297_CR13","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","volume":"27","author":"JH Foster","year":"2021","unstructured":"Foster, J. H. et al. Activity of crizotinib in patients with ALK-aberrant relapsed\/refractory neuroblastoma: a Children\u2019s Oncology Group study (ADVL0912). Clin. Cancer Res. 27, 3543\u20133548 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2297_CR14","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Mosse","year":"2017","unstructured":"Mosse, Y. P. et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study. J. Clin. Oncol. 35, 3215\u20133221 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2297_CR15","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1158\/0008-5472.CAN-14-3817","volume":"75","author":"ER Tucker","year":"2015","unstructured":"Tucker, E. R., Danielson, L. S., Innocenti, P. & Chesler, L. Tackling crizotinib resistance: the pathway from drug discovery to the pediatric clinic. Cancer Res. 75, 2770\u20132774 (2015).","journal-title":"Cancer Res."},{"key":"2297_CR16","first-page":"373","volume":"6","author":"D Chand","year":"2013","unstructured":"Chand, D. et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis. Model Mech. 6, 373\u2013382 (2013).","journal-title":"Dis. Model Mech."},{"key":"2297_CR17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"SC Bresler","year":"2014","unstructured":"Bresler, S. C. et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26, 682\u2013694 (2014).","journal-title":"Cancer Cell"},{"key":"2297_CR18","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-15-0379","volume":"22","author":"K Krytska","year":"2016","unstructured":"Krytska, K. et al. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin. Cancer Res. 22, 948\u2013960 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2297_CR19","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"TW Johnson","year":"2014","unstructured":"Johnson, T. W. et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 57, 4720\u20134744 (2014).","journal-title":"J. Med. Chem."},{"key":"2297_CR20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20, 1691\u20131701 (2019).","journal-title":"Lancet Oncol."},{"key":"2297_CR21","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw, A. T. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 18, 1590\u20131599 (2017).","journal-title":"Lancet Oncol."},{"key":"2297_CR22","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon, B. J. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19, 1654\u20131667 (2018).","journal-title":"Lancet Oncol."},{"key":"2297_CR23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714\u2013729 (2018).","journal-title":"Cancer Discov."},{"key":"2297_CR24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","volume":"37","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J. Clin. Oncol. 37, 1370\u20131379 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2297_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/2159-8290.CD-15-1056","volume":"6","author":"NR Infarinato","year":"2016","unstructured":"Infarinato, N. R. et al. The ALK\/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov. 6, 96\u2013107 (2016).","journal-title":"Cancer Discov."},{"key":"2297_CR26","doi-asserted-by":"crossref","first-page":"e26940","DOI":"10.1002\/pbc.26940","volume":"65","author":"JG Villablanca","year":"2018","unstructured":"Villablanca, J. G. et al. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr. Blood Cancer 65, e26940 (2018).","journal-title":"Pediatr. Blood Cancer"},{"key":"2297_CR27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","volume":"20","author":"TA Clark","year":"2018","unstructured":"Clark, T. A. et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J. Mol. Diagn. 20, 686\u2013702 (2018).","journal-title":"J. Mol. Diagn."},{"key":"2297_CR28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer, T. M. et al. Clinical management of adverse events associated with lorlatinib. Oncologist 24, 1103\u20131110 (2019).","journal-title":"Oncologist"},{"key":"2297_CR29","doi-asserted-by":"crossref","unstructured":"Park, J. R. et al. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer 128, 3775\u20133783 (2022).","DOI":"10.1002\/cncr.34445"},{"key":"2297_CR30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324\u20131334 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2297_CR31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Moss\u00e9","year":"2013","unstructured":"Moss\u00e9, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472\u2013480 (2013).","journal-title":"Lancet Oncol."},{"key":"2297_CR32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2012.228","volume":"307","author":"NK Cheung","year":"2012","unstructured":"Cheung, N. K. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062\u20131071 (2012).","journal-title":"JAMA"},{"key":"2297_CR33","unstructured":"Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279\u2013284 (2013)."},{"key":"2297_CR34","volume":"11","author":"SW Brady","year":"2020","unstructured":"Brady, S. W. et al. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nat. Commun. 11, 5183 (2020).","journal-title":"Nat. Commun."},{"key":"2297_CR35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/pbc.24777","volume":"61","author":"YP Moss\u00e9","year":"2014","unstructured":"Moss\u00e9, Y. P. et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr. Blood Cancer 61, 627\u2013635 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"2297_CR36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccell.2019.09.002","volume":"36","author":"ZA Qadeer","year":"2019","unstructured":"Qadeer, Z. A. et al. ATRX in-frame fusion neuroblastoma is sensitive to EZH2 inhibition via modulation of neuronal gene signatures. Cancer Cell 36, 512\u2013527 (2019).","journal-title":"Cancer Cell"},{"key":"2297_CR37","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-19-3068","volume":"80","author":"B Koneru","year":"2020","unstructured":"Koneru, B. et al. Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma. Cancer Res. 80, 2663\u20132675 (2020).","journal-title":"Cancer Res."},{"key":"2297_CR38","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/cas.15363","volume":"113","author":"MR van Gerven","year":"2022","unstructured":"van Gerven, M. R. et al. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics. Cancer Sci. 113, 2167\u20132178 (2022).","journal-title":"Cancer Sci."},{"key":"2297_CR39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21247-8","volume":"12","author":"SA Hartlieb","year":"2021","unstructured":"Hartlieb, S. A. et al. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nat. Commun. 12, 1269 (2021).","journal-title":"Nat. Commun."},{"key":"2297_CR40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13578-022-00896-2","volume":"12","author":"A Meeser","year":"2022","unstructured":"Meeser, A. et al. Reliable assessment of telomere maintenance mechanisms in neuroblastoma. Cell Biosci. 12, 160 (2022).","journal-title":"Cell Biosci."},{"key":"2297_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00072","volume":"3","author":"A Roderwieser","year":"2019","unstructured":"Roderwieser, A. et al. Telomerase is a prognostic marker of poor outcome and a therapeutic target in neuroblastoma. JCO Precis. Oncol. 3, 1\u201320 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"2297_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26870-z","volume":"12","author":"K Schmelz","year":"2021","unstructured":"Schmelz, K. et al. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Nat. Commun. 12, 6804 (2021).","journal-title":"Nat. Commun."},{"key":"2297_CR43","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1158\/1078-0432.CCR-15-0423","volume":"21","author":"A Bellini","year":"2015","unstructured":"Bellini, A. et al. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin. Cancer Res. 21, 4913\u20134921 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2297_CR44","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.0.CO;2-I","volume":"91","author":"K Kramer","year":"2001","unstructured":"Kramer, K., Kushner, B., Heller, G. & Cheung, N. K. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer 91, 1510\u20131519 (2001).","journal-title":"Cancer"},{"key":"2297_CR45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMc2101264","volume":"385","author":"A Bagchi","year":"2021","unstructured":"Bagchi, A. et al. Lorlatinib in a child with ALK-fusion-positive high-grade glioma. N. Engl. J. Med. 385, 761\u2013763 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2297_CR46","doi-asserted-by":"crossref","unstructured":"Bosse, K. R. et al. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma. Cancer Discov. 12, 2800\u20132819 (2022).","DOI":"10.1158\/2159-8290.CD-22-0287"},{"key":"2297_CR47","first-page":"491","volume":"51","author":"M Parisi","year":"2010","unstructured":"Parisi, M. et al. Impact of MIBG scores on predicting survival in high risk neuroblastoma patients. J. Nucl. Med. 51, 491 (2010).","journal-title":"J. Nucl. Med."},{"key":"2297_CR48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur, G. M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466\u20131477 (1993).","journal-title":"J. Clin. Oncol."},{"key":"2297_CR49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0959-8049(94)00509-4","volume":"31A","author":"N Ady","year":"1995","unstructured":"Ady, N. et al. A new 123I-MIBG whole body scan scoring method\u2014application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur. J. Cancer 31A, 256\u2013261 (1995).","journal-title":"Eur. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02297-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T23:37:46Z","timestamp":1702165066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02297-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. Y.P.M. is the principal investigator of the NANT phase 1 trial of lorlatinib and is a consultant for Pfizer. Y.P.M. has previously received research funding from Pfizer and Novartis. Y.P.M. has also served as a consultant for Lilly, Auron Therapeutics and Jumo Health. Y.P.M. serves as a member of the Data and Safety Monitoring Committee for the ASCO TAPUR study and receives honoraria for this role. H.T. is an employee of Pfizer and holds Pfizer stock. J.S. was an employee of Pfizer during the conduct and analysis of this work, currently owns Pfizer stock and is currently employed by Roche-Genentech. M.L. is a postdoctoral fellow with funding supported by Pfizer. G.P., at the time of study, was employed by Pfizer and held company stock. A.M. and NANT clinical research operations received funding from Pfizer in support of this study. K.C.G. has been an uncompensated consultant to Y-mAbs Therapeutics. L.M. has been a consultant or advisor for Bayer, Bristol Myers Squibb, Illumina and Tesaro and served as an EDMC member on studies run by Eisai and Merck. A.D. has stock ownership in Pfizer and Viatris and has acted as a paid consultant or advisor for Merck, Ology Medical Education, Y-mAbs Therapeutics and GlaxoSmithKline. D.A.M. has been a consultant or advisory board member to Y-mAbs Therapeutics, Clarity Pharmaceuticals, RayzeBio and Oncoheroes Biosciences. G.S. has received research funding from Bristol Myers Squibb, MSDavenir, Roche and Pfizer for research projects distinct from this trial. K.M. is a consultant with Y-mabs Therapeutics and RayzeBio. R.M. is on the Data and Safety Monitoring Committee for Y-Mabs Therapeutics and Jubilant Draximage. M.M. has stock in Johnson & Johnson, GE Healthcare and Varian Medical Systems. M.M. has been a consultant or advisory board memebr to Y-mAbs Therapeutics and has received research funding from Bayer, Ignyta, Roche, Lilly, Merck, Oncternal Therapeutics, AbbVie, Jubilant Draxlmage and Actuate Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}